Bibliografía del artículo
1. UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC; 2010 Disponível em http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
2. Ministério da Saúde. Boletim Epidemiológico AIDS-DST. Brasília, DF: Ministério da Saúde; 2010. Disponível em http://www.aids.gov.br
3. Tapia C, Gonzales P, Pereira A, Pérez J, Noriega LM, Palavecino ES. Susceptibilidad antifúngica de Candida albicans recuperadas de pacientes com SIDA y candidiasis orofaríngea y esofágica. Revista Médica de Chile 131:515-519, 2003.
4. WHO. Investing in a Comprehensive Health Sector Response to AIDS/HIV. Jan. 2004-Dec. 2005. http://www.who.int /3by5/en/HIV_AIDSplan.pdf
5. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrobial Agents and Chemotherapy 41:535-539, 1997.
6. Samaranayake LP. Oral mycoses in human immunodeficiency vírus infection: a review. Oral surgery, Oral Medicine, Oral Pathology 73:171-180, 1992.
7. Reedding SWMA, Pfaller SA, Messer JA, Smith J, Prows LL, Bradley AW, Fothergill MG. Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. Journal of Clinical Microbiology 35:1761-1765, 1997.
8. Achkar JM, Fries BC. Candida Infections of the Genitourinary Tract. Clinical Microbiology Reviews 23:253-273, 2010.
9. Same-Ekobo A, Lohoue J, Mbassi A. A clinical and biological study of parasitic and fungal diarrhea in immunossuppressed patients in urban suburban area of Yaounde. Sante 7:49-354, 1997.
10. Pfaller MA, Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clinical Microbiology and Infection 10:11-23, 2004.
11. Sanchez-Vargas lO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda lA, Quindós G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Revista Iberoamericana de Micologia 22:83-92, 2005.
12. McGinnis MR, RinaldiI MG. Antifungical Drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In: Victor Lorian MD. Antibiotics in laboratory medicine. Washington D.C.: Willians & Wilkins; 1996.
13. Schechter M. Rachid M. Manual de HIV/AIDS. Revinter, Rio de Janeiro; 2004.
14. Vazquez JA. Management of oropharyngeal and esophageal candidiasis in patients with HIV infection. Journal of HIV Therapy 4:1-19, 2010.
15. Singleton DR, Hazen KC. Differential surface localization and temperature-dependent expression of the Candida albicans CSH1 protein. Microbiology 150:285-292, 2004.
16. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. TRENDS in Microbiology 9:327-335, 2001.
17. Ivanoska N. Phospholipases as a factor of pathogenicity in microorganisms. Journal of Molecular Catalysis B: Enzymatic 22:357-61, 2003.
18. Weinberg ED. Iron and infection. Microbiological Reviews 42:45-66, 1978.
19. Manns JM, Mosser DM, Buckley HR. Production of a hemolytic factor by Candida albicans. Infection and Immunity 62:5154-5156, 1994.
20. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual Of Clinical Microbiology. 6a ed., Washington DC: ASM Press; 1995.
21. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activity of Voriconazole and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agentes and Chemoterapy 42:161-163, 1998.
22. Houang ET, Chu KC, Koehler AP, Cheng AF. Use of CHROMagar Candida for genital specimens in the diagnostic laboratory. Journal of Clinical Pathology 50:563-565, 1997.
23. CLSI. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M27-A. Clinical and Laboratory Standards Institute. Wayne, Pennsylvania, EE.UU.; 2005.
24. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Oral Candida isolates colonizing or infecting human immunodeficiency virus infected and healthy persons in Mexico J Clin Microbiol 43(8):4159-62, 2005.
25. Favalessa OC, Martins Mdos A, Hahn RC. Mycological aspects and susceptibility in vitro the yeast of the genus Candida from HIV-positive patients in the State of Mato Grosso..Rev Soc Bras Med Trop 43(6):673-7, 2010.
26. Vandeputte P, Larcher G, Bergès T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis.Antimicrob Agents Chemother 49(11):4608-15, 2005.
27. Bizerra FC, Nakamura CV, de Poersch C, Estivalet Svidzinski TI, Borsato Quesada RM, Goldenberg S, Krieger MA, Yamada-Ogatta SF. Characteristics of biofilm formation by Candida tropicalis and antifungal resistance.FEMS Yeast Res 8(3):442-50, 2008.
28. Negri M, Martins M, Henriques M, Svidzinski TI, Azeredo J, Oliveira R. Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycopathologia 169(3):175-82, 2010.
29. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42(10):4419-31, 2004.
30. Fidel PL Jr, Vazquez JA, Sobel JD Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12(1):80-96, 1999.
31. Nucci M, Colombo AL. Emergence of resistant Candida in neutropenic patients. Braz J Infect Dis 2002 Jun;6(3):124-8. Epub 2003. Review.
32. Hachem R, Sipsas NV, Lewis RE, Tarrand J, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115(20):4745-52, 2009.
33. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50(7):2522-4, 2006.
34. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities.J Clin Microbiol 39(8):2971-4, 2001.
35. França EJ, Fávero D, Scremin H, Oliveira MT, Furlaneto-Maia L, Quesada RM, Furlaneto MC. Hemolysis produced by Candida tropicalis isolates from clinical samples Rev Soc Bras Med Trop 43(3):318-21, 2010.